The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.
A network meta-analysis of 32 randomized trials found that balanced crystalloid solutions were associated with lower mortality, reduced acute kidney injury, and shorter hospital stays in patients with sepsis or septic shock.
A multicenter study of pediatric patients treated with fidaxomicin for C difficile found over half were cured by two weeks, and only one in five had a recurrence within two months.